DECIPHERA PHARMACEUTICALS IN's ticker is DCPH and the CUSIP is 24344T101. A total of 90 filers reported holding DECIPHERA PHARMACEUTICALS IN in Q3 2018. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $1,328,426 | +1086.1% | 92,060 | +727.5% | 0.00% | – |
| Q4 2021 | $112,000 | -92.2% | 11,125 | -71.5% | 0.00% | -100.0% |
| Q2 2021 | $1,437,000 | +7.3% | 39,102 | +29.7% | 0.00% | 0.0% |
| Q1 2021 | $1,339,000 | -45.6% | 30,146 | -34.3% | 0.00% | -50.0% |
| Q4 2020 | $2,460,000 | +2.8% | 45,864 | +7.8% | 0.00% | 0.0% |
| Q3 2020 | $2,392,000 | -1.0% | 42,550 | -3.6% | 0.00% | 0.0% |
| Q2 2020 | $2,416,000 | +120700.0% | 44,156 | +105033.3% | 0.00% | – |
| Q1 2020 | $2,000 | -98.8% | 42 | -98.4% | 0.00% | – |
| Q4 2019 | $167,000 | +165.1% | 2,692 | +44.5% | 0.00% | – |
| Q3 2019 | $63,000 | +125.0% | 1,863 | +52.3% | 0.00% | – |
| Q2 2019 | $28,000 | +833.3% | 1,223 | +848.1% | 0.00% | – |
| Q4 2018 | $3,000 | +50.0% | 129 | +108.1% | 0.00% | – |
| Q3 2018 | $2,000 | 0.0% | 62 | +12.7% | 0.00% | – |
| Q2 2018 | $2,000 | – | 55 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| New Leaf Venture Partners, L.L.C. | 1,209,571 | $72,236,000 | 20.73% |
| SV Health Investors, LLC | 449,951 | $26,871,000 | 18.64% |
| Redmile Group, LLC | 4,978,941 | $297,342,000 | 5.49% |
| Sunesis Advisors, LLC | 96,299 | $5,751,000 | 5.29% |
| Eversept Partners, LP | 418,652 | $25,001,897 | 3.43% |
| Opaleye Management Inc. | 222,000 | $13,081,000 | 2.64% |
| Avoro Capital Advisors LLC | 1,860,000 | $111,079,000 | 2.20% |
| SPHERA FUNDS MANAGEMENT LTD. | 282,965 | $16,899,000 | 1.59% |
| SECTORAL ASSET MANAGEMENT INC | 224,359 | $13,399,000 | 1.23% |
| Artal Group S.A. | 650,000 | $38,818,000 | 1.09% |